LIXTE BIOTECHNOLOGY HOLDINGS INC

For the period ended Dec 31, 2023. Filed Mar 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 19, 2024

NMAD$3.57-0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

In accordance with Section 13 and 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 19, 2024		LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		(Registrant)
	By:	/s/ BASTIAAN VAN DER BAAN
	Name:	Bastiaan van der Baan
	Title:	President and Chief Executive Officer

In accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacity and on the dates indicated.

John S. Kovach
Signature	Title	Date
/s/ BASTIAAN VAN DER BAAN	President and Chief Executive Officer	March 19, 2024
/s/ ROBERT N. WEINGARTEN	Vice President and Chief Financial Officer	March 19, 2024
Robert N. Weingarten
/s/ STEPHEN J. FORMAN	Director	March 19, 2024
Stephen J. Forman
/s/ RENE BERNARDS	Director	March 19, 2024
René Bernards
/s/ YUN YEN	Director	March 19, 2024
Yun Yen
/s/ REGINA BROWN	Director	March 19, 2024
Regina Brown

-96-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.